Live Feed

Delayed 3m

Press · Analyst · Insider · Buys · Financials

Signed out · 3-min delay · Sign up for real-time

PR11:00:00·3m·Health Care·
$BMY
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos, adding to the longest-running clinical development experience for a cardiac myosin inhibitor (CMI) in symptomatic oHCM Additional presentations at ESC Congress build upon the established effectiveness and safety profile of Camzyos in real-world settings Bristol Myers Squibb (NYSE:BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest evaluation of symptomatic obstructive hypertrop
PR10:30:00·33m·Health Care·
$CYTK
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Function in Patients with Non-Obstructive HCM New Analysis of MAPLE-HCM Finds Aficamten Outperformed Metoprolol Across Pre-Trial Treatment Groups in Patients with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in a Late Breaking Clinical Session at the Eu
PR08:21:22·2h·Health Care·
$TENX
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo With full statistics analysis now complete, Company confirms TNX-103’s biological effects include marked reductions in pulmonary artery pressure and NT-proBNP, a biomarker reflecting increased cardiac wall stress. Results will inform protocol population enrichment and changes to overall registrational path CHAPEL HILL, N.C., Aug. 29, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeu
INSIDER21:53:58·13h·Finance·
$JEF
CEO Handler Richard B was granted 75,531 shares, increasing direct ownership by 0.60% to 12,625,397 units (SEC Form 4)
4 - Jefferies Financial Group Inc. (0000096223) (Issuer)
INSIDER21:53:12·13h·Finance·
$JEF
President Friedman Brian P was granted 29,016 shares, increasing direct ownership by 1% to 2,037,263 units (SEC Form 4)
4 - Jefferies Financial Group Inc. (0000096223) (Issuer)
INSIDER21:52:12·13h·Finance·
$JEF
EVP, CFO Larson Matthew Scott was granted 746 shares, increasing direct ownership by 0.75% to 99,756 units (SEC Form 4)
4 - Jefferies Financial Group Inc. (0000096223) (Issuer)
INSIDER21:51:28·13h·Consumer Discretionary·
$VTSI
Director Barber Grant bought $10,136 worth of shares (3,350 units at $3.03), increasing direct ownership by 16% to 24,392 units (SEC Form 4)
4 - VirTra, Inc (0001085243) (Issuer)
INSIDER21:50:59·13h·Finance·
$JEF
Director Weiler Melissa was granted 165 shares, increasing direct ownership by 0.41% to 40,147 units (SEC Form 4)
4 - Jefferies Financial Group Inc. (0000096223) (Issuer)
INSIDER21:51:40·13h·Finance·
$JEF
EVP and General Counsel Sharp Michael J. was granted 746 shares, increasing direct ownership by 0.44% to 168,409 units (SEC Form 4)
4 - Jefferies Financial Group Inc. (0000096223) (Issuer)
INSIDER21:49:19·13h·Finance·
$JEF
Director O Kane Michael T was granted 538 shares, increasing direct ownership by 0.41% to 133,030 units (SEC Form 4)
4 - Jefferies Financial Group Inc. (0000096223) (Issuer)
INSIDER21:49:57·13h·Finance·
$JEF
Director Ellis-Kirk Matrice was granted 165 shares, increasing direct ownership by 0.52% to 32,147 units (SEC Form 4)
4 - Jefferies Financial Group Inc. (0000096223) (Issuer)
INSIDER21:48:35·13h·Finance·
$JEF
Director Beyer Robert D was granted 501 shares, increasing direct ownership by 0.44% to 113,257 units (SEC Form 4)
4 - Jefferies Financial Group Inc. (0000096223) (Issuer)
INSIDER21:37:03·13h·Telecommunications·
$OPTU
Large owner Subin Neil S bought $2,454,822 worth of shares (3,032,354 units at $0.81) (SEC Form 4)
4 - Optimum Communications, Inc. (0001702780) (Issuer)
INSIDER21:36:41·13h·Telecommunications·
$OPTU
New insider Subin Neil S claimed ownership of 16,516,955 shares (SEC Form 3)
3 - Optimum Communications, Inc. (0001702780) (Issuer)
INSIDER21:35:06·13h·Health Care·
$NTRA
PRESIDENT, CHIEF BUS. OFFICER Fesko John was granted 20,000 shares and sold $2,095,411 worth of shares (6,517 units at $321.53) as part of a pre-agreed trading plan, increasing direct ownership by 7% to 197,257 units (SEC Form 4) (tax liability)
4 - Natera, Inc. (0001604821) (Issuer)
INSIDER21:30:10·13h·Industrials·
$EVTL
SEC Form 4 filed by Chief Executive Officer Simpson Stuart
4 - Vertical Aerospace Ltd. (0001867102) (Issuer)
INSIDER21:01:49·14h·Health Care·
$BIVI
Chief Medical Officer Palumbo Joseph M bought $10,461 worth of shares (4,843 units at $2.16), increasing direct ownership by 406% to 6,036 units (SEC Form 4)
4 - BIOVIE INC. (0001580149) (Issuer)
INSIDER21:01:21·14h·Health Care·
$BIVI
Director Chappell Amy Suzon bought $1,570 worth of shares (727 units at $2.16) (SEC Form 4)
4 - BIOVIE INC. (0001580149) (Issuer)
INSIDER21:00:04·14h·Consumer Discretionary·
$MRM
Chief Executive Officer Eguchi Kouji disposed of 79,945 shares, decreasing direct ownership by 4% to 1,797,515 units (SEC Form 4)
4 - Medirom Healthcare Technologies Inc. (0001819704) (Issuer)
INSIDER20:58:13·14h·Health Care·
$BIVI
Chief Financial Officer Kim Joanne Wendy bought $5,450 worth of shares (2,500 units at $2.18), increasing direct ownership by 266% to 3,441 units (SEC Form 4)
4 - BIOVIE INC. (0001580149) (Issuer)